

PDMR Dealing

Oxford, UK - 08 December 2025: OXB (LSE: OXB) (the "Company"), a global quality and innovation-led cell and gene therapy CDMO, today announces that Lisa Doman, Chief People Officer and Kyriacos Mitrophanous, Chief Innovation Officer have exercised their respective 3,057 SAYE 2022 options at an exercise price of £2.944 on 08 December 2025 and disposed of their respective 3,057 shares at an average price of £6.23026 per share on 08 December 2025.

The below notifications, made in accordance with the requirements of the EU Market Abuse Regulation, give further details of the transaction.

1.	Details of the Person Discharging Managerial Responsibility ("PDMR")/person closely associated with them ("PCA")		
a)	Name	Lisa Doman	
2.	Reason for the notification		
a)	Position/status	Person Discharging Managerial Responsibility	
b)	Initial notification/ amendment	Initial Notification	
3.	Details of the Issuer		
a)	Full name of the entity	Oxford Biomedica plc	
b)	LEI code	213800S1GVQNXQ15K851	
4.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted		
a)	Date of the transaction	2025-12-08	
b)	Description of the financial instrument	SAYE Options over Ordinary Shares of 50 pence each	
c)	Identification code	ISIN: GB00BDFBVT43	
d)	Nature of the transaction	Exercise of SAYE 2022 Options at £2.944	
e)	Place of the transaction	Outside the trading venue	
f)	Currency	GBP - British pound	
g)	Price(s) and volumes(s)	Price(s)	Volume(s)
		£2.944	3,057
h)	Aggregated information		
	- Aggregate volume	3,057	
	- Price	£2.944	
	- Aggregated total	£8999.81	

1.	Details of the Person Discharging Managerial Responsibility ("PDMR")/person closely associated with them ("PCA")	
a)	Name	Lisa Doman
2.	Reason for the notification	
a)	Position/status	Person Discharging Managerial Responsibility

b)	Initial notification/ amendment	Initial Notification		
3.	Details of the Issuer			
a)	Name	Oxford Biomedica plc		
b)	LEI code	213800S1GVQNXQ15K851		
4.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted			
a)	Date of the transaction	2025-12-08		
b)	Description of the financial instrument	Ordinary Shares of 50 pence each		
c)	Identification code	ISIN: GB00BDFBVT43		
d)	Nature of transaction	Sale of shares		
e)	Place of the transaction	London Stock Exchange, Main Market (XLON)		
f)	Currency	GBP - British pound		
g)	Price(s) and volumes(s)	Price(s)	Volume(s)	
		£6.23026	3,057	
h)	Aggregated information			
	- Aggregate volume	3,057		
	- Price	£6.23026		
	- Aggregated total	£19,045.90		

1.	Details of the Person Discharging Managerial Responsibility ("PDMR")/person closely associated with them ("PCA")		
a)	Name	Kyriacos Mitrophanous	
2.	Reason for the notification		
a)	Position/status	Person Discharging Managerial Responsibility	
b)	Initial notification/ amendment	Initial Notification	
3.	Details of the Issuer		
a)	Full name of the entity	Oxford Biomedica plc	
b)	LEI code	213800S1GVQNXQ15K851	
4.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted		
a)	Date of the transaction	2025-12-08	
b)	Description of the financial instrument	SAYE Options over Ordinary Shares of 50 pence each	
c)	Identification code	ISIN: GB00BDFBVT43	
d)	Nature of the transaction	Exercise of SAYE 2022 Options at £2.944 exercise price	
e)	Place of the transaction	Outside of the trading venue	
f)	Currency	GBP - British pound	
g)	Price(s) and volumes(s)	Price(s)	Volume(s)
		£2.944	3,057
h)	Aggregated information		
	- Aggregate volume	3,057	
	- Price	£2.944	
	- Aggregated total	£8999.81	

1.	Details of the Person Discharging Managerial Responsibility ("PDMR")/person closely associated with them ("PCA")						
a)	Name	Kyriacos Mitrophanous					
2.	Reason for the notification						
a)	Position/status	Person Discharging Managerial Responsibility					
b)	Initial notification/ amendment	Initial Notification					
3.	Details of the Issuer						
a)	Name	Oxford Biomedica plc					
b)	LEI code	213800S1GVQNXQ15K851					
4.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted						
a)	Date of the transaction	2025-12-08					
b)	Description of the financial instrument	Ordinary Shares of 50 pence each					
c)	Identification code	ISIN: GB00BDFBVT43					
d)	Nature of transaction	Sale of shares					
e)	Place of the transaction	London Stock Exchange, Main Market (XLON)					
f)	Currency	GBP - British pound					
g)	Price(s) and volumes(s)	<table><tr><td>Price(s)</td><td>Volume(s)</td></tr><tr><td>£6.23026</td><td>3,057</td></tr></table>	Price(s)	Volume(s)	£6.23026	3,057	
Price(s)	Volume(s)						
£6.23026	3,057						
h)	Aggregated information <ul style="list-style-type: none">- Aggregate volume- Price- Aggregated total	<table><tr><td>3,057</td></tr><tr><td>£6.23026</td></tr><tr><td>£19,045.90</td></tr></table>		3,057	£6.23026	£19,045.90	
3,057							
£6.23026							
£19,045.90							

-Ends-

Enquiries:

OXB:

Natalie Walter, Chief Legal Officer and Company Secretary - T: +44 (0) 1865 783 000 / E: cosec@oxb.com

ICR Healthcare:

T: +44 (0)20 3709 5700 / E: oxb@icrhealthcare.com

Mary-Jane Elliott / Angela Gray / Davide Salvi

About OXB

OXB (LSE: OXB) is a global quality and innovation-led contract development and manufacturing organisation (CDMO) in cell and gene therapy with a mission to enable its clients to deliver life changing therapies to patients around the world.

One of the original pioneers in cell and gene therapy, OXB has 30 years of experience in viral vectors; the driving force behind the majority of cell and gene therapies. OXB collaborates with some of the world's most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV), adenovirus and other viral vector types. OXB's world-class capabilities range from early-stage development to commercialisation. These capabilities are supported by robust quality-assurance systems, analytical methods and depth of regulatory expertise.

OXB offers a vast number of technologies for viral vector manufacturing, including a 4th generation lentiviral vector system (the TetraVecta™ system), a dual-plasmid system for AAV production, suspension and perfusion process using process enhancers and stable producer and packaging cell lines.

OXB, a FTSE250 and FTSE4Good constituent, is headquartered in Oxford, UK. It has development and manufacturing facilities across Oxfordshire, UK, Lyon and Strasbourg, France, Bedford MA, and Durham NC, US. Learn more at www.oxb.com and follow us on [LinkedIn](#) and [YouTube](#).

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact ms@seg.com or visit www.ms.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

DSHPKFBDPBDDKBK